Latest news with #EstablishmentInspectionReport
Business Upturn
2 hours ago
- Business
- Business Upturn
Top stocks to watch on August 11: Tata Motors, Dr. Reddy's Laboratories, IDFC First Bank, Zydus and more
By Aman Shukla Published on August 11, 2025, 08:19 IST Several companies are in focus today, Monday, August 11, following notable earnings reports, regulatory approvals, and other corporate developments. Stocks To Watch Today Oil Marketing Companies (OMCs): The government has approved ₹30,000 crore as compensation for LPG under-recoveries. Dr. Reddy's Laboratories (DRL): The US FDA has issued an Establishment Inspection Report (EIR) for its CTO-5 manufacturing unit in Telangana, classifying it as 'Voluntary Action Indicated' (VAI). DOMS Industries: Q1 revenue rose 26% year-on-year (YoY), while EBITDA increased 14% YoY. Lemon Tree Hotels: Average room rate increased 10% YoY, with EBITDA margin at 44.5% compared to 43% last year. Power Mech Projects: EBITDA rose 49% YoY, margin improved to 13.2% from 11.3% a year ago. Entero Healthcare: EBITDA increased 63% YoY, margin at 3.5% compared to 2.8% last year. DCW Ltd: EBITDA grew 18.4% YoY, margin improved to 11.4% from 9% last year. IDFC First Bank: Platinum Invictus B 2025 RSC received RBI approval for its proposed investment in the bank. Brigade Enterprises: Launched 'Brigade Cherry Blossom' project in East Bengaluru, with revenue potential of ₹225 crore. Shilpa Medicare: Received CDSCO approval for NorUDCA tablets, used in treatment of non-alcoholic fatty liver disease. Zydus Lifesciences: Received final US FDA approval for Prucalopride tablets. BEML: Secured its first overseas contract from Malaysia worth $1 million. NIBE Ltd: Won export order from Israel for ship-mounted universal rocket launching systems. ICICI Bank: Increased minimum balance requirement for new accounts effective August 1. Tata Motors: Reported mixed Q1 results against muted estimates; volumes declined across categories. Siemens: Q3FY25 EBITDA margin came in lower than estimates, net profit 7% below expectations. Manappuram Finance: Q1 results below estimates; calculated NIM fell 80 bps quarter-on-quarter. Home First Finance: Range Clove likely to sell its entire 10.3% equity stake via block deals at a 0-5% discount to CMP. Voltas: Q1 results below estimates; margin declined to 4.5% from 8.6% YoY. Ceigall India: EBITDA fell 24% YoY, margin down to 13% from 17.4%. Dhampur Sugar: EBITDA declined 16.5% YoY, margin at 3% versus 4% last year. Shipping Corporation of India: EBITDA fell 4% YoY, revenue down 13%. Puravankara: Reported a net loss compared to profit last year; revenue fell 20% YoY. TVS Supply Chain Solutions: EBITDA declined 2.2% YoY, margin at 6.83% versus 7.12%. Suprajit Engineering: Margin fell to 9.47% from 11.74% last year; EBITDA declined 5.3% YoY. Ahmedabad Plane Crash Dr Reddy's LaboratoriesIDFC First BankTata MotorsZydus Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
Business Upturn
3 days ago
- Business
- Business Upturn
Dr. Reddy's Laboratorie gets EIR from USFDA for Telangana facility with VAI status
By Aman Shukla Published on August 8, 2025, 16:24 IST Dr. Reddy's Laboratories has received the Establishment Inspection Report (EIR) from the US Food and Drug Administration (USFDA) for its API manufacturing facility (CTO 5) in Miryalaguda, Telangana. The EIR was issued on August 7, 2025, following a GMP inspection that was earlier conducted and disclosed by the company on May 24, 2025. The USFDA has classified the outcome of the inspection as 'Voluntary Action Indicated (VAI)' , meaning the agency has closed the inspection with some observations, but no further regulatory action is anticipated at this time. The inspection is officially considered closed under 21 CFR 20.64(d)(3). A VAI classification typically indicates that the facility remains compliant for continued supply to the US market. This update should bring some regulatory clarity and comfort to stakeholders and investors. Ahmedabad Plane Crash Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
Business Standard
30-07-2025
- Business
- Business Standard
Innoxel Lifesciences successfully completes USFDA inspection of its Vadodara unit
Bharat Parenterals announced that its subsidiary, Innoxel Lifesciences, has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (U.S. FDA) for its finished dosage manufacturing facility in Vadodara, Gujarat. This follows the successful completion of the U.S. FDA inspection conducted from April 28 to May 2, 2025. The facility is capable of manufacturing, packaging, testing, storage and distribution of two types of complex dosage forms - Liquid Injectables and Oral Liquids. With the receipt of the EIR, Innoxel Lifesciences has also received acceptance of the site for commercial operations for the product(s) under inspection. This milestone reinforces Innoxel's commitment to global quality benchmarks and enhances its capability to supply high-quality pharmaceutical products to regulated markets, such as United States and the European Union.
Business Upturn
24-07-2025
- Business
- Business Upturn
Natco Pharma gets EIR from USFDA for Hyderabad API facility
NATCO Pharma Limited has announced that it has received the Establishment Inspection Report (EIR) from the U.S. Food and Drug Administration (FDA) for its Active Pharmaceutical Ingredient (API) facility located in Mekaguda, Hyderabad. This follows a recent inspection that was carried out between June 9 and June 13, 2025. During the inspection, the FDA issued one observation under Form 483, which was classified as 'Voluntary Action Indicated' (VAI). This classification implies that the issues noted are not serious enough to warrant any regulatory or enforcement action, and NATCO can voluntarily correct them. With the EIR now issued on July 24, 2025, it signals the closure of the inspection process, which is generally a positive outcome for the company. NATCO Pharma, based in Hyderabad, is known for its focus on research-driven, specialty and generic pharmaceuticals, including strong capabilities in oncology and targeted therapies in the domestic market. The company also has a strong presence in the U.S. market, particularly in limited-competition molecules. In addition to pharmaceuticals, NATCO is active in crop protection products. The company operates nine manufacturing facilities and two R&D centers across India, with approvals from major global regulators such as the US FDA, Health Canada, ANVISA (Brazil), and the WHO. NATCO currently serves over 50 international markets. Ahmedabad Plane Crash Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
Time of India
23-07-2025
- Business
- Time of India
Syngene Q1 profit up 59% to Rs 87 crore
Representative image BENGALURU: Syngene International, a subsidairy of Biocon , reported a 59 per cent year-on-year increase in profit after tax to Rs 87 crore in the first quarter ended June 2025, aided by revenue growth and a tax benefit from the transfer of gratuity funds to an employee trust. Revenue from operations rose 11 per cent to Rs 875 crore during the period. Ebitda grew 19 per cent year-on-year to Rs 224 crore, with margins improving to 25 per cent from 23 per cent a year earlier. CEO Peter Bains said the growth was led by the conversion of pilot programs into long-term contracts in the Research Services division. The company also progressed operations at its Biologics Unit III facility in Bengaluru and prepared for the launch of its Bayview site in the US later this year. It commissioned a new peptide laboratory during the quarter. The company said it underwent over 20 client and regulatory audits in Q1, including a USFDA GCP inspection of its Human Pharmacology Unit with no observations. Its Biologics facility received an Establishment Inspection Report with a Voluntary Action Indicated outcome. CFO Deepak Jain said operating Ebitda margins held around 24 per cent, supported by revenue growth and cost optimisation. Syngene said it remains on track to meet its full-year guidance. Stay informed with the latest business news, updates on bank holidays and public holidays . AI Masterclass for Students. Upskill Young Ones Today!– Join Now
